Navigation Links
Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
Date:7/17/2019

Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).

Through this collaboration, AveXis, a Novartis company, will have dedicated manufacturing space at the new, state-of-the-art commercial manufacturing center near Baltimore-Washington International Airport established by Paragon Gene Therapy, a unit of Catalent Biologics. This additional capacity, along with access to Catalent’s adeno-associated virus (AAV) gene therapy development, manufacturing, and process characterization expertise, will allow for secure market supply of the treatment which is newly approved in the United States. Paragon Gene Therapy will also provide process development for clinical supply of additional viral therapies in the AveXis pipeline.

SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis, and when left untreated in its most severe form, permanent ventilation or death for most patients by age 2. Zolgensma is designed to address the genetic root cause of SMA by replacing the defective or missing SMN1 gene to halt disease progression through sustained SMN protein expression with a single one-time intravenous infusion. Zolgensma is the first and only gene therapy approved by the U.S. Food and Drug Administration for the treatment of SMA, including in patients who are pre-symptomatic at diagnosis.

“We are pleased to add additional manufacturing capacity and technical expertise through this collaboration as we rapidly scale up product production,” commented Andy Stober, Senior Vice President of Technical Operations for AveXis. “We look forward to working with Catalent in continued service of the SMA community.”

“We are honored to be a partner in this transformational journey,” added Pete Buzy, Catalent’s President, Gene Therapy. “This collaboration allows us to leverage our new state-of-art GMP commercial manufacturing facility and AAV development and scale-up expertise to support AveXis from the early development stage to this critical launch. We work tirelessly to support a patient-first culture, and we are fully committed to be a premier collaborator with AveXis as they deliver this incredible new treatment for patients.”

About Paragon Gene Therapy
Paragon Gene Therapy, a unit of Catalent Biologics, is an industry leader focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, and oncology immunotherapies. Paragon Gene Therapy has two facilities in Baltimore, Maryland dedicated to process development through commercial manufacturing of most scalable AAV platforms across multiple serotypes. Since 2016, Paragon Gene Therapy has completed over 100 clinical GMP AAV batches across 40 programs.

About Catalent Biologics
For more than two decades, Catalent Biologics has built capabilities and experience in development, manufacturing, and analytical services for new biological entities, gene vectors, biosimilars, and antibody-drug conjugates. Catalent has worked with 600+ mAbs and 80+ proteins, and more than 115 clinical trials and 11 marketed products have used GPEx® cell line engineering technology. A further 20 commercially-approved products have employed Catalent Biologics’ capabilities through to aseptic fill/finish. Catalent’s latest addition, Paragon Gene Therapy’s AAV development through commercial-scale manufacturing facilities in Baltimore, Maryland, have produced over 100 clinical GMP batches across 40 programs. Using advanced protein improvement technology and tailored solutions from DNA through to clinical and commercial supply, Catalent Biologics brings better biologic treatments to patients, faster. For more information, visit biologics.catalent.com

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Zolgensma® is a registered trademark of AveXis, Inc. a Novartis company.

Read the full story at https://www.prweb.com/releases/catalent_biologics_announces_agreement_to_provide_additional_production_of_approved_gene_therapy_treatment_for_spinal_muscular_atrophy/prweb16443185.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
2. Patient-Focused Drug Delivery to be Presented by Catalent at PODD
3. Lipid-Based Drug Delivery in Modern Pharmaceutical Development to be Presented by Catalent and BASF at Forthcoming Workshop
4. Catalent Biologics Announces Collaboration with Therachon, Switzerland, to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia
5. Catalent Executives to Present on Clinical Trial Supply Management and Optimizing Product Development at Upcoming BioPharma Asia Conference
6. Portages Biohaven enters into exclusive formulation agreement and global license with Catalent for lead product
7. Object Pharma Announces Strategic Acquisition of Metabiologics
8. Signature Biologics Announces Entry Into the Perinatal Allograft Tissue Market With Commercially Available Flowable Umbilical Cord and Amniotic Allograft Tissue Products
9. Molecular Devices Announces Brand Identity for Its Newly-Formed Biologics Business Unit
10. American Farmer Educates on Recent Advances in Biologics for Food Production
11. Heritage Biologics launches innovative HBnow virtual care program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/8/2019)... OTTAWA, Canada (PRWEB) , ... September 05, 2019 ... ... today announced that Blaine Fitzgerald, former Vice President of Finance for Shopify, has ... CFO Russ Jones and healthcare venture capitalist Joel Finlayson as strategic advisors. Additionally, ...
(Date:8/29/2019)... CENTURY, Kan. (PRWEB) , ... August 28, 2019 ... ... innovation expertise and wide-ranging DuPont™ Danisco® ingredient solutions to attendees at the International ... science to solve today’s baking challenges from optimizing production efficiency to cost and ...
(Date:8/25/2019)... ... August 23, 2019 , ... Authors Gopal Nayak and ... scientific research book “Impact of Biofield Treatment on Growth and Anatomical Characteristics of ... , The book garnered No. 1 status on Amazon in several categories ...
(Date:8/14/2019)... (PRWEB) , ... August 13, 2019 , ... ... receptor and in vitro toxicology testing solutions, announced the appointment of Mark McLoughlin ... experience to the Board. , Mark McLoughlin will lend his healthcare expertise and ...
Breaking Biology Technology:
(Date:8/29/2019)... ... 2019 , ... Lajollacooks4u has expanded its team as it gears up for ... has seen record growth in 2019, having hosted a multitude of team-building events and ... all visited the company’s La Jolla-based venue, and Lajollacooks4u has worked hard to accommodate ...
(Date:8/27/2019)... (PRWEB) , ... August 26, 2019 , ... Shoreline ... to the strain level, has hired Bill McKenzie as its CEO and Karen Woodward ... to help Shoreline Biome meet growing demand for its products and expand the company’s ...
(Date:8/27/2019)... VIEJO, Calif. (PRWEB) , ... August 27, 2019 ... ... genetics testing company, announced today new opportunities to improve genetic testing guidelines. In ... how to improve the guidelines to identify more at-risk patients. , Clinicians ...
Breaking Biology News(10 mins):